ISG15 and neoplasm: We demonstrated, for the first time, as a proof of concept, that vaccination against ISG15 with Lm-LLO-ISG15 significantly controlled the CRC tumor burden in both subcutaneous and orthotopic syngeneic CRC mouse models (Figure 3 and Figure 4).